To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.

SARS-CoV-2 Infection Clinical Trial

Official title:

A Phase l, Single-blind, Placebo-controlled Trial Designed to Assess the Safety and Tolerability of a Single Intravenous Dose of MTx-COVAB36 in Healthy Volunteers.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05351437
• Other study ID #: MTx-COVAB36-AU-1.02CoV
• Status: Completed
• Phase: Phase 1
• Start date: April 26, 2022
• Est. completion date: November 2, 2022

Study information

• Verified date: November 2022
• Source: Memo Therapeutics AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single blind, placebo-controlled clinical trial designed to determine the safety and tolerability of MTx-COVAB36 after a single administration in a dose escalation, dose limiting toxicity (DLT)-driven approach in healthy volunteers. Additional data to define the recommended phase II dose (RP2D) will also be determined.

MTx-COVAB36 is a fully human monoclonal IgG1 antibody derived from the memory B cells of convalescent COVID-19 donors and directed against SARS-CoV-2 spike protein with potent virus neutralising activity.

The trial will comprise four dose cohorts, each composed of 6 participants receiving MTx-COVAB36 and 2 participants receiving placebo, with pre-defined dose levels. The pre-defined investigational medicinal product (IMP) doses are: 100 mg, 500 mg, 1,000 mg and 2,000 mg, respectively. Participants will be administered a single dose of either IMP or placebo on Day 1 of the study and will be followed up until 63 days post administration.

Description:

Despite the rapid rollout of vaccines against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), there is still a need for therapeutic and prophylactic treatments against the Coronavirus Disease 2019 (COVID-19) especially for those individuals who are not sufficiently protected by vaccines, i.e., a significant proportion of people of older age, the immunocompromised and those having various comorbidities.

MTx-COVAB36 is a fully human monoclonal IgG1 antibody derived from the memory B cells of convalescent COVID-19 donors and directed against SARS-CoV-2 spike protein with potent virus neutralising activity.

This is a single blind, placebo-controlled clinical trial designed to determine the safety and tolerability of MTx-COVAB36 after a single administration in a dose escalation, DLT-driven approach in healthy volunteers. Additional data to define the RP2D will also be determined.

The trial will comprise four dose cohorts, each composed of 6 participants receiving MTx-COVAB36 and 2 participants receiving placebo, with pre-defined dose levels. The pre-defined IMP doses are: 100 mg, 500 mg, 1,000 mg and 2,000 mg, respectively. Participants will be administered a single dose of either IMP or placebo on Day 1 of the study and will be followed up until 63 days post administration.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: November 2, 2022
• Est. primary completion date: September 4, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Healthy male or female participants aged 18 years to 50 years at the time of consent

2. Ability to read, understand and provide written informed consent

3. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

4. Healthy participants as established by medical history, laboratory examination, physical examination, vital signs, and ECG during screening and as per the clinical judgment of the investigator

5. Body mass index (BMI) 18.0 to 32.0 kg/m2 (inclusive)

6. For Woman of Childbearing Potential (WOCBP): agrees to practice true abstinence or agrees to use a highly effective method of contraception consistently from 30 days prior to Day 1 until end of the study (Day 63). Highly effective contraception includes hormonal contraception, placement of intrauterine device (IUD) or intrauterine system (IUS), or a vasectomized partner (performed at least 6 months prior to her screening) who has been documented to no longer produce sperm. Verbal confirmation from the participant through medical interview is acceptable. No contraception requirements for participants in exclusive same-sex relationship.

7. For male participant: must agree to practice true abstinence or use condom if he has a partner of childbearing potential, or must be surgically sterilized (performed at least 6 months prior and documented to no longer produce sperm. Verbal confirmation through medical nterview is acceptable). Participant to practice abstinence (if applicable) or use condom until end of the study (Day 63). No contraception requirements for participants in exclusive same-sex relationship.

8. Accessible veins in the forearms for venepuncture and/or intravenous cannulation

Exclusion Criteria:

1. Participant with active SARS-CoV-2 infection, verified by RT-PCR test

2. Participants tested positive for human immunodeficiency virus (HIV antibody screen), Hepatitis B virus (HBsAg screen) or Hepatitis C virus (HCV antibody screen)

3. History of administration of any investigational or non-registered drug within 30 days or 5 half-lives, whichever is longer, prior to administration of study drug, or planned administration during the course of study participation

4. History of any reaction to monoclonal antibodies

5. History of clinically relevant atopic diseases and/or known allergies to the trial product or its components

6. History of any major pulmonary, cardiovascular, renal, neurological (e.g., cerebrovascular events), metabolic, gastrointestinal, hepato-biliary, or hematological functional abnormality, malignancy (except for adequately treated basal cell carcinoma or squamous cell carcinoma of the skin), or mental disability as per discretion of the investigator

7. Any clinically significant laboratory findings at screening and enrolment and at Day-1; one retest is allowed at screening and/or at Day-1

8. Acute illness (moderate or severe) and/or fever (body temperature = 38 °C) during the 72 hours prior to planned study drug application

9. Participants with altered immunocompetence such as participants with ongoing cancer treatment, human immunodeficiency virus infection, organ transplant or any other active immune system disorder

10. Receipt of immunoglobulin or blood products within 6 months prior to enrolment

11. Receipt of a monoclonal antibody within previous 6 months or 5 half-lives, whichever is longer

12. Planned surgery (excluding minor procedures such as tooth extraction or incision and drainage) during the course of the study

13. Receipt of any standard vaccine within 14 days prior to Day 1

14. History of alcoholism or drug addiction (as per DSM-V) within 1 year prior to screening

15. Use of prescription drugs within 7 days prior to Day 1 or for 5 half-lives whichever is longer, or during the study, except for hormonal contraceptives or positive result in urine drug screen or alcohol breath test at screening or Day-1

16. Use of over-the-counter medication within 7 days prior to Day 1 or during the study; medication such as paracetamol and ibuprofen may be permitted at the discretion of the investigator and sponsor

17. Receipt of immunosuppressive medications within 6 months prior to enrolment, or any active or prior history of immunodeficiency (receipt of any course of systemic corticosteroids for more than a 7-day duration and with a prednisolone equivalent dose of more than 5 mg per day within 6 months prior to enrolment will exclude a participant; inhaled or topical steroids are allowed)

18. Pregnant, lactating, or planned pregnancy during the study period

19. Inability to comply with the study protocol in the opinion of the investigator

20. Participant has any plans to permanently relocate from the area prior to the completion of the study or to leave for an extended period of time when study visits would need to be scheduled

21. Concurrent participation in another interventional clinical study investigating a vaccine, drug, medical device, or medical procedure in the 30 days preceding the study drug administration or during the course of the study

22. Abnormal vital signs including systolic blood pressure (SBP) < 90 or > 150 mmHg, diastolic blood pressure (DBP) < 40 or > 90 mmHg, heart rate (HR) < 40 or > 100 bpm (average of triplicate measurements) at screening

Related Conditions & MeSH terms

• COVID-19
• SARS-CoV-2 Infection

Intervention

Drug:
• MTx-COVAB36
MTx-COVAB36 is a fully human monoclonal IgG1 antibody derived from the memory B cells of convalescent COVID-19 donors and directed against SARS-CoV-2 spike protein with potent virus neutralising activity.
• Placebo
0.9% saline

Locations

Country	Name	City	State
Australia	Linear Clinical Research	Nedlands	Western Australia

Sponsors (1)

Lead Sponsor	Collaborator
Memo Therapeutics AG

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	To investigate the incidence, severity and causal relationship of AEs following single dose IV administration of MTx-COVAB36 to healthy volunteers.	Day 1 (IMP administration day) to Day 63 (Final visit)
Secondary	Pharmacokinetics measured by the maximum plasma concentration (Cmax)	To describe the pharmacokinetics of MTx-COVAB36 in healthy volunteers after single dose intravenous administration.	Day 1 (IMP administration day) to Day 63 (Final visit)
Secondary	Pharmacokinetics measured by the area under the concentration-time curve (AUC)	To describe the pharmacokinetics of MTx-COVAB36 in healthy volunteers after single dose intravenous administration.	Day 1 (IMP administration day) to Day 63 (Final visit)
Secondary	Pharmacokinetics measured by the apparent clearance (CL)	To describe the pharmacokinetics of MTx-COVAB36 in healthy volunteers after single dose intravenous administration.	Day 1 (IMP administration day) to Day 63 (Final visit)
Secondary	Pharmacokinetics measured by the terminal half-life (t1/2)	To describe the pharmacokinetics of MTx-COVAB36 in healthy volunteers after single dose intravenous administration.	Day 1 (IMP administration day) to Day 63 (Final visit)
Secondary	Immunogenicity measured by anti-drug antibody (ADA) production	Assessment of the incidence and intensity of ADA production	Day 1 (IMP administration day), Day 8 and Day 29 post-administration and at Day 63 (final visit).
Secondary	Immunogenicity measured by drug neutralizing antibody (Nab) production	Assessment of the incidence and intensity of Nab production.	Day 1 (IMP administration day), Day 8 and Day 29 post-administration and at Day 63 (final visit).